Dosage form with sustained release melatonin pellets
A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material.
1. A composition comprising a therapeutically effective oral pharmaceutical dosage form comprising:
(a) an aqueous carrier material having an acidic pH; and
(b) a plurality of individual pellets having a first dose of melatonin therein, the individual pellets comprising (i) a solid core; (ii) an active coating over the solid core, the active coating including the first dose of melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating, a dissolution pH of the enteric coating being higher than the acidic pH of the aqueous carrier material,
wherein the aqueous carrier material comprises a second dose of melatonin therein, and
wherein the oral pharmaceutical dosage form is configured to release the second dose of melatonin into an oral cavity and stomach of a subject to whom the composition is administered.
2. The composition of claim 1 , wherein the first dose of melatonin is a powder having a median melatonin particle size of 5 μm to 40 μm.
3. The composition of claim 1 , wherein the oral pharmaceutical dosage form is a beverage, and the aqueous carrier material includes water.
4. The composition of claim 1 , wherein the oral pharmaceutical dosage form is a gummy, and the aqueous carrier material is a gummy gelling agent.
5. The composition of claim 1 , wherein:
the individual pellets further comprise a separation coating over the active coating, a subcoat over the separation coating, and an enteric coating over the subcoat;
the subcoat includes a hydrogel-forming polymer and an acid, the acid imparting a pH of 0.1 to 4.4 to the hydrogel-forming polymer; and
the separation coating separates the acid from the first dose of melatonin.
6. The composition of claim 5 , wherein the aqueous carrier material is hydroxypropyl methylcellulose, the solid core is a microcrystalline cellulose bead having a diameter of 0.1 to 2 mm, the hydrophilic binder includes hydroxypropyl methylcellulose, the first dose of melatonin is a powder having a median melatonin particle size of 5 μm to 40 μm lodged in the hydrophilic binder, the separation coating includes hydroxypropyl methylcellulose, the hydrogel-forming polymer includes hydroxypropyl methylcellulose, the acid includes citric acid, and the separation coating includes hydroxypropyl methylcellulose.
7. A method comprising administering a therapeutically effective amount of an oral pharmaceutical dosage form to a patient in need thereof, the oral pharmaceutical dosage form comprising:
(a) an aqueous carrier material having an acidic pH; and
(b) a plurality of individual pellets having a first dose of melatonin therein, the individual pellets comprising (i) a solid core; (ii) an active coating over the solid core, the active coating including the first dose of melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating, a dissolution pH of the enteric coating being higher than the acidic pH of the aqueous carrier material,
wherein the aqueous carrier material comprises a second dose of melatonin therein, and
wherein the oral pharmaceutical dosage form is configured to release the second dose of melatonin into an oral cavity and stomach of a subject to whom the composition is administered.
8. The method of claim 7 , wherein the first dose of melatonin is a powder having a median melatonin particle size of 5 μm to 40 μm.
9. The method of claim 7 , wherein the oral pharmaceutical dosage form is a beverage, and the aqueous carrier material includes water.
10. The method of claim 7 , wherein the oral pharmaceutical dosage form is a gummy, and the aqueous carrier material is a gummy gelling agent.
11. The method of claim 7 , wherein:
the individual pellets further comprise a separation coating over the active coating, a subcoat over the separation coating, and an enteric coating over the subcoat;
the subcoat includes a hydrogel-forming polymer and an acid, the acid imparting a pH of 0.1 to 4.4 to the hydrogel-forming polymer; and
the separation coating separates the acid from the melatonin.
12. The method of claim 11 , wherein the aqueous carrier material is hydroxypropyl methylcellulose, the solid core is a microcrystalline cellulose bead having a diameter of 0.1 to 2 mm, the hydrophilic binder includes hydroxypropyl methylcellulose, the first dose of melatonin is a powder having a median melatonin particle size of 5 μm to 40 μm lodged in the hydrophilic binder, the separation coating includes hydroxypropyl methylcellulose, the hydrogel-forming polymer includes hydroxypropyl methylcellulose, the acid includes citric acid, and the separation coating includes hydroxypropyl methylcellulose.
13. The method of claim 7 , wherein the dosage form is therapeutically effective for assisting the patient to sleep.
14. A method comprising:
combining an aqueous carrier material with a plurality of individual pellets to form a therapeutically effective oral pharmaceutical dosage form;
the aqueous carrier material having an acidic pH; and
the plurality of individual pellets having a first dose of melatonin therein, the individual pellets comprising (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating, a dissolution pH of the enteric coating being higher than the acidic pH of the aqueous carrier material,
wherein the aqueous carrier material comprises a second dose of melatonin therein, and
wherein the oral pharmaceutical dosage form is configured to release the second dose of melatonin into an oral cavity and stomach of a subject to whom the composition is administered.
15. The method of claim 14 , wherein the first dose of melatonin is a powder having a median melatonin particle size of 5 μm to 40 μm.
16. The method of claim 14 , wherein the oral pharmaceutical dosage form is a beverage, and the aqueous carrier material includes water.
17. The method of claim 14 , wherein the oral pharmaceutical dosage form is a gummy, and the aqueous carrier material is a gummy gelling agent.
18. The method of claim 14 , wherein:
the individual pellets further comprise a separation coating over the active coating, a subcoat over the separation coating, and enteric coating over the subcoat;
the subcoat includes a hydrogel-forming polymer and an acid, the acid imparting a pH of 0.1 to 4.4 to the hydrogel-forming polymer; and
the separation coating separates the acid from the first dose of melatonin.
19. The method of claim 18 , wherein the aqueous carrier material is hydroxypropyl methylcellulose, the solid core is a microcrystalline cellulose bead having a diameter of 0.1 to 2 mm, the hydrophilic binder includes hydroxypropyl methylcellulose, the first dose of melatonin is a powder having a median melatonin particle size of 5 μm to 40 μm lodged in the hydrophilic binder, the separation coating includes hydroxypropyl methylcellulose, the hydrogel-forming polymer includes hydroxypropyl methylcellulose, the acid includes citric acid, and the separation coating includes hydroxypropyl methylcellulose.